Investigator Initiated Research Areas of Interest
Takeda and its alliance partners are committed to improving patient care by supporting scientific advances in medicine and increasing our understanding of important diseases. As part of this commitment, the IIR program supports innovative interventional and noninterventional and basic science studies that address important medical and scientific questions related to our compounds and therapeutic Areas of Interest (AOI).
IIR is defined as an unsolicited research study where the Investigator, organization or institution (academic, private, or governmental) serves as the Sponsor, and Takeda provides support only in the form of funding, study product, safety information and/or authorization to reference Takeda’s NDA or other regulatory submissions (e.g., IND). Takeda does not provide input in an IIR other than providing the above support.
Takeda reviews completed proposals both within and outside of the Areas of Interest (AOI) listed throughout this document.
All proposals will be evaluated in adherence with Takeda policies and all applicable laws and regulations. Decisions are based upon scientific merit as well as alignment with research areas of interest and availability of resources. Submission of a proposal does not imply or guarantee approval. Support of a study in no way implies any obligation toward or is any way connected to the recommendation or prescribing of products.
We are not accepting new IIRs for this area
Secondary Immunodeficiency (SID):
Primary Immunodeficiency (PID):
For disease related, non-product specific areas of interest please visit Hereditary Angioedema (HAE) section of the website (see above).
Contact Seagen for US or Canadian proposals
Currently not accepting proposals
Out of Scope
This information is intended to provide knowledge of current investigator-initiated research areas of interest and may include studies on investigational treatments and/or unapproved use of marketed products. There can be no guarantee that any products will be approved for sale, or new indications approved for existing products, in any market. Prescribers should refer to their local Prescribing Information. Patients who have healthcare- or treatment-related questions, should contact their healthcare provider.